1. Scrip
  2. >>Business

VectivBio Seeks Slice Of Short Bowel Syndrome Market

As Offering Brings In $125m

 
• By Kevin Grogan

The Switzerland-headquartered group believes it has a potentially best-in-class GLP-2 agonist on its hands with apraglutide, which has proved effective in a subgroup of patients that do not benefit from standard of care Gattex.

High jump
Apraglutide clears clinical bar • Source: Archive

Having just raised $125m and presented promising mid-stage data on apraglutide, VectivBio Holding AG is making strides in its bid to become the leading player in the short bowel syndrome (SBS) space currently dominated by Takeda Pharmaceutical Co. Ltd.'s Gattex.

The Swiss biotech, established in May 2019 as a spin-off from Therachon Holding AG following the latter's $810m acquisition...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

More from Business

Syncona Looks To Go Private As Market Decline Deepens

 
• By Andrew McConaghie

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Top 10 Drugs Q1 2025: Keytruda Dominates; Mounjaro Climbs

 
• By Eleanor Malone

Lilly’s Mounjaro for diabetes rose from sixth to third position among the top-selling drugs in the first quarter of 2025, Rival Ozempic retained second position and Merck & Co’s immuno-oncology blockbuster Keytruda stayed far ahead.